Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.41 |
| ▸ | MTOR | P42345 | 3/20 | 0.41 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | HCK | P08631 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.41 |
| ▸ | PRKDC | P78527 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13850008 | 0.98 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3PIK3CAMTOR | |
| SCHEMBL6488330 | 0.93 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3CHRNB1CHRNB2 | |
| SCHEMBL6488329 | 0.93 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3CHRNB1CHRNB2 | |
| SCHEMBL7210045 | 0.81 | SLC6A3 (0.58) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5830066 | 0.77 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5830069 | 0.77 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3 | |
| Oxalic Acid SCHEMBL7214943 | 0.75 | SLC6A3 (0.54) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7214954 | 0.74 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3CHRNB1CHRNB2 | |
| SCHEMBL7209988 | 0.74 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3CHRNB2CHRNB4 | |
| SCHEMBL7210016 | 0.74 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3CHRNB2CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0984966-B1 | 9-AZABICYCLO(3.3.1)NON-2-ENE AND NONANE DERIVATIVES AS CHOLINERGIC LIGANDS AT NICOTINIC ACh RECEPTORS | NEUROSEARCH AS (DK) | 2003-01-29 | — | — | EP | claimed |
| US-6392045-B1 | 9-azobicyclo[3.3.1] non-2-ene derivatives as cholinergic ligands at nicotinic ACH receptors | NEUROSEARCH A/S (DK) | 2002-05-21 | — | — | US | claimed |
| EP-0984966-A1 | 9-AZABICYCLO(3.3.1)NON-2-ENE AND NONANE DERIVATIVES AS CHOLINERGIC LIGANDS AT NICOTINIC ACh RECEPTORS | NEUROSEARCH A/S (DK) | 2000-03-15 | — | — | EP | claimed |
| WO-1998054182-A1 | 9-AZABICYCLO(3.3.1)NON-2-ENE AND NONANE DERIVATIVES AS CHOLINERGIC LIGANDS AT NICOTINIC ACh RECEPTORS | NEUROSEARCH A/S (DK) | 1998-12-03 | — | — | WO | claimed |
| US-20090118326-A1 | Nicotinic Acetylcholine Receptor Modulators | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-05-07 | — | — | US | disclosed |
| EP-0984966-B1 | 9-AZABICYCLO(3.3.1)NON-2-ENE AND NONANE DERIVATIVES AS CHOLINERGIC LIGANDS AT NICOTINIC ACh RECEPTORS | NEUROSEARCH AS (DK) | 2003-01-29 | — | — | EP | disclosed |
| US-6392045-B1 | 9-azobicyclo[3.3.1] non-2-ene derivatives as cholinergic ligands at nicotinic ACH receptors | NEUROSEARCH A/S (DK) | 2002-05-21 | — | — | US | disclosed |
| EP-0984966-A1 | 9-AZABICYCLO(3.3.1)NON-2-ENE AND NONANE DERIVATIVES AS CHOLINERGIC LIGANDS AT NICOTINIC ACh RECEPTORS | NEUROSEARCH A/S (DK) | 2000-03-15 | — | — | EP | disclosed |
| WO-1998054182-A1 | 9-AZABICYCLO(3.3.1)NON-2-ENE AND NONANE DERIVATIVES AS CHOLINERGIC LIGANDS AT NICOTINIC ACh RECEPTORS | NEUROSEARCH A/S (DK) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118326-A1 | Nicotinic Acetylcholine Receptor Modulators | CHRNA10, CHRNA6, CHRNA5 | SLC6A2 510/4885SLC6A4 1198/4885SLC6A3 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.